Myriagon develops effective, non-addictive oral analgesics for neuropathic pain. They have discovered a novel analgesic for chemotherapy-induced peripheral neuropathy (CIPN), a debilitating side effect of chemotherapy characterized by burning sensations and severe pain. CIPN is a major cause of dose reduction and discontinuation of chemotherapy, and approximately 30% of patients experience chronic symptoms. Currently, no approved treatments exist, leading patients to rely on off-label use of various drug classes, including opioids, which offer limited relief and may cause serious side effects such as physical dependence. Myriagon aims to address this critical unmet medical need by developing safe and effective analgesics.

They have discovered and patented peripherally restricted monoacylglycerol lipase (MAGL) inhibitors. In animal models of CIPN, oral administration of their lead compound has demonstrated complete pain relief without physical dependence. Their MAGL inhibitor leverages anti-inflammatory mechanisms, offering potential applications beyond CIPN in other types of pain and inflammation. Supporting this, efficacy has been demonstrated in multiple pain and inflammation models. Myriagon believes this approach has the potential to become a highly effective non-steroidal anti-inflammatory analgesic.

Are you also interested to pitch your company at the next edition of Health~Holland Global Investor Forum and Innovation for Health on 10-11 March 2027 in Utrecht, the Netherlands? Then sign up for the event newsletter to stay informed.